Physician profile
Hatem Ali
NPI 1821259466
$10,939.05
in general payments reported to CMS, 2019-2025
25 companies · $2,674 in 2025
The $2,674 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2021: $939 · 2022: $2,830 · 2023: $2,024 · 2024: $2,083 · 2025: $2,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,673 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,673.17 |
| Education | $108.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,792.46 | 2019-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $1,145.82 | 2022-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $1,125.32 | 2021-2025 | |
| Vifor Pharma, INC. | $913.55 | 2019-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $872.34 | 2021-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $783.12 | 2022-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $714.20 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $654.55 | 2021-2025 | Benlysta |
| Amgen INC. | $530.45 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Calliditas Therapeutics US INC. | $409.49 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $358.77 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.51 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $241.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $150.63 | 2023-2025 | |
| Baxter Healthcare | $125.00 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $124.99 | 2025 | Ultomiris |
| Veloxis Pharmaceuticals, INC. | $124.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $122.96 | 2022-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $102.18 | 2021-2023 | Velphoro |
| Nxstage Medical, INC. | $100.32 | 2024 | |
| Opko Pharmaceuticals, LLC | $75.57 | 2022-2025 | Rayaldee |
| Novo Nordisk INC | $45.72 | 2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $34.09 | 2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $29.51 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $17.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hatem Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.